Download Company information PDF

Dizlin Pharmaceuticals AB

Stockholm – SWE

Dizlin Pharmaceuticals AB is a Swedish research-based pharmaceutical company dedicated to developing innovative treatments for advanced stages of Parkinson disease. Collaborating with the University of Gothenburg and Linköping University, Dizlin has developed two key products:

  • Infudopa SubC™
  • Infudopa IntraV™

Founding year

2003

Industry

Pharmaceutical
Book a meeting
Sign Letter of Intent

Björn Velin

CEO
Dizlin mission is to improve the quality of life for Parkinson patients by offering effective and convenient treatment options that address the limitations of current therapies. Dizlin’s innovative approach has the potential to significantly reduce motor complications associated with traditional levodopa administration.
businessman-working-at-laptop-taking-notes-in-not-2022-12-16-22-27-36-utc.jpg
Björn-v2-800px-300x300

Björn Velin

CEO
Dizlin mission is to improve the quality of life for Parkinson patients by offering effective and convenient treatment options that address the limitations of current therapies. Dizlin’s innovative approach has the potential to significantly reduce motor complications associated with traditional levodopa administration.
Linkedin